Compare · BDX vs IRTC
BDX vs IRTC
Side-by-side comparison of Becton Dickinson and Company (BDX) and iRhythm Holdings Inc. (IRTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and IRTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 12.0x IRTC ($3.64B).
- BDX has been more active in the news (8 items in the past 4 weeks vs 3 for IRTC).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- iRhythm Holdings Inc.
- Price
- -
- -
- Market cap
- $43.58B
- $3.64B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest IRTC
- iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026
- EVP, Strategy & Corp Devt Freeman Sean Clinton sold $114,484 worth of shares (918 units at $124.71), decreasing direct ownership by 6% to 13,641 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang sold $177,462 worth of shares (1,423 units at $124.71), decreasing direct ownership by 3% to 53,620 units (SEC Form 4) to satisfy withholding tax
- 16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
- SEC Form 8-K filed by iRhythm Holdings Inc.
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 133 shares and sold $185,652 worth of shares (1,716 units at $108.19), decreasing direct ownership by 4% to 40,287 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Rosenbaum Marc Wade was granted 178 shares and sold $78,870 worth of shares (729 units at $108.19), decreasing direct ownership by 3% to 16,155 units (SEC Form 4) to cover withholding tax
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang was granted 137 shares, increasing direct ownership by 0.25% to 55,043 units (SEC Form 4)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 177 shares, increasing direct ownership by 0.30% to 58,341 units (SEC Form 4)